Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Questcor to Commence Trading on NASDAQ Today


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-05-16 12:31:54 -

- Questcor Pharmaceuticals, Inc. Don Bailey or Steve Cartt, 510-400-0700 IR2@Questcor.com or EVC Group Doug Sherk or Dahlia Bailey, 415-896-6820 Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) announced the company's common stock will commence trading today, May 16, 2008, on The NASDAQ Capital Market under the stock symbol QCOR.

"Questcor is very pleased to join NASDAQ," said Don Bailey, President

and Chief Executive Officer of Questcor Pharmaceuticals. "Our objective is to provide added visibility to our investors, and we believe NASDAQ's multiple market maker structure provides the largest liquidity pool and will enhance the exposure of our company's stock. The NASDAQ Stock Market is recognized as the home of the world's leading brands, with more shares trading on average per day than any other U.S. market."

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar(R) Gel ("Acthar") and Doral(R), and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS"). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.

New Stock Symbol QCOR




Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com